Anterolisthesis is a spinal condition in which one vertebra slips forward relative to the vertebra directly below it. It is the most common form of spondylolisthesis and most frequently occurs at the L4-L5 or L5-S1 levels of the lumbar spine, where mechanical stresses are highest. The forward displacement -even when modest -disrupts the normal alignment of the spinal column and can lead to disc degeneration, nerve irritation, and persistent pain.
For patients living with anterolisthesis who have not found adequate relief through conservative care, stem cell therapy for anterolisthesis is an emerging regenerative option that aims to address the disc and tissue degeneration contributing to spinal instability.
Understanding Anterolisthesis
The word “anterolisthesis” comes from the Latin anterior (front) and the Greek olisthesis (to slip). It is distinct from retrolisthesis, where the vertebra slips backward. The condition is graded on a scale from I to IV based on the percentage of forward displacement:
- Grade I: Less than 25% displacement
- Grade II: 25–50% displacement
- Grade III: 50–75% displacement
- Grade IV: 75–100% displacement
Most patients with symptomatic degenerative anterolisthesis present with Grade I or II, where disc degeneration and facet joint deterioration allow gradual forward translation of the vertebra. Higher-grade cases may involve structural fractures (isthmic spondylolisthesis) and may require more intensive intervention.
What Is the Best Treatment for Anterolisthesis?
The answer depends on severity, the presence of neurological symptoms, and how the patient has responded to conservative treatment. Management typically follows this progression:
Conservative care (first-line):
- Physical therapy focused on core stabilization and spinal alignment
- Activity modification and posture correction
- NSAIDs and non-opioid analgesics for pain management
- Epidural steroid injections for radicular or nerve-related pain
Surgical intervention:
Spinal fusion is reserved for Grade III–IV cases, or Grade I–II cases with significant neurological compromise or failure to improve after sustained conservative treatment. Clinical guidelines support a conservative-first approach in most patients with degenerative anterolisthesis without severe neurological symptoms (Matz et al., Spine J., 2016).
Regenerative medicine (emerging option):
For patients between these extremes -chronic symptoms not responding to conservative care, but without severe instability or neurological compromise -stem cell therapy for anterolisthesis offers a possible bridge option.
How Stem Cell Therapy Addresses Anterolisthesis
The disc and facet joint degeneration underlying anterolisthesis is what stem cell therapy targets. Mesenchymal stem cells (MSCs) -obtained from bone marrow aspirate concentrate (BMAC) or adipose-derived MSC preparations -are injected into the degenerated intervertebral disc or surrounding structures.
MSCs are thought to contribute in several ways:
- Supporting disc tissue integrity: By releasing growth factors and bioactive molecules, MSCs may help maintain disc cell populations and extracellular matrix components that give discs their height and load-distributing capacity
- Reducing local inflammation: Chronic disc degeneration is associated with ongoing inflammatory signaling; MSCs can modulate this environment through paracrine effects
- Slowing progression: Addressing disc degeneration early may help prevent the progressive forward slip from advancing to higher grades over time
A pilot study examining autologous bone marrow MSC injection into degenerated lumbar discs demonstrated both safety and meaningful improvement in patient pain and disability scores at 12-month follow-up, with MRI evidence of disc hydration improvement in some cases (Orozco et al., Transplantation, 2011).
Safety and outcomes data from regenerative medicine practice has also demonstrated a favorable profile for culture-expanded MSC re-injection into spinal structures, supporting the feasibility of these approaches in clinical settings (Centeno et al., Curr Stem Cell Res Ther., 2011).
Understanding the degenerative process in lumbar spondylolisthesis -including the relationship between disc degeneration, facet arthrosis, and vertebral slippage -informs why regenerative approaches targeting disc integrity may help stabilize the segment over time (Kalichman & Hunter, Eur Spine J. 2008).
Cervical Anterolisthesis
While most cases of anterolisthesis occur in the lumbar spine, stem cell therapy for cervical anterolisthesis is also an area of interest. Cervical anterolisthesis -forward slippage in the neck -is less common and often detected on imaging in the context of cervical spondylosis. For symptomatic cervical cases with disc degeneration, MSC-based regenerative injection into cervical discs is theoretically applicable, though clinical data specific to this location is more limited. Evaluation by a spine specialist is essential for cervical cases.
What to Expect With Stem Cell Treatment for Anterolisthesis
Before: Clinical evaluation with current MRI or CT imaging to assess grade of slippage, disc degeneration severity, and the presence of any neurological compromise.
During: Bone marrow harvest (typically from the iliac crest) or adipose harvest, followed by processing and intradiscal injection under fluoroscopic or ultrasound guidance.
After: Reduced mechanical loading for 2–4 weeks, with gradual return to activity. Improvement in pain and function typically develops over 3–6 months as the disc and surrounding structures respond.
Frequently Asked Questions
Can stem cell therapy stabilize an this condition?
Stem cell therapy targets the disc degeneration that contributes to spinal instability. By supporting disc health and reducing inflammatory stress on the segment, it may help slow progression, though it cannot mechanically realign a slipped vertebra. Structural stabilization remains the goal of surgical fusion in severe cases.
Is forward vertebral slippage curable without surgery?
Grade I and mild Grade II this spinal condition often stabilizes with conservative management and does not progress. Regenerative approaches may further support stability by addressing the underlying disc degeneration, but outcomes vary by individual.
How do I know if I’m a candidate for stem cell therapy for the slippage?
Ideal candidates typically have Grade I or II degenerative vertebral displacement with chronic symptoms despite conservative treatment, without severe neurological compromise. A spine specialist evaluation including current imaging is needed to assess candidacy.
How long does improvement take after treatment?
Most patients begin to notice changes within 6–12 weeks, with fuller improvement developing over 3–6 months as the disc and surrounding tissue respond to the regenerative stimulus.
Key Takeaways
- This condition involves forward vertebral slippage most commonly at L4-L5 or L5-S1
- Grade I and II degenerative cases are the most common and most amenable to non-surgical management
- Stem cell therapy for forward vertebral slippage uses MSCs to support disc integrity, reduce inflammation, and address the structural basis of instability
- Clinical evidence for intradiscal MSC therapy in disc degeneration shows safety and meaningful patient improvement
- This approach is best suited for patients between conservative care and surgical fusion on the severity spectrum
- A thorough clinical evaluation and imaging review are essential before proceeding
To explore whether stem cell therapy may be appropriate for your spinal condition, schedule a stem cell therapy consultation or schedule a consultation with our medical team at Ways2Well.
References
- Orozco L, Soler R, Morera C, Alberca M, Sánchez A, García-Sancho J. “Intervertebral disc repair by autologous mesenchymal bone marrow cells: a pilot study.” Transplantation. 2011;92(7):822–828. DOI: https://doi.org/10.1097/TP.0b013e3182298a15
- Centeno CJ, Schultz JR, Cheever M, et al. “Safety and complications reporting update on the re-injection of culture-expanded mesenchymal stem cells using autologous platelet lysate technique.” Curr Stem Cell Res Ther. 2011;6(4):368–378. DOI: https://doi.org/10.2174/157488811797904033
- Kalichman L, Hunter DJ. “Diagnosis and conservative management of degenerative lumbar spondylolisthesis.” Eur Spine J. 2008;17(3):327–335. DOI: https://doi.org/10.1007/s00586-007-0543-3
- Matz PG, Meagher RJ, Lamer T, et al. “Guideline summary review: An evidence-based clinical guideline for the diagnosis and treatment of degenerative lumbar spondylolisthesis.” Spine J. 2016;16(3):439–448. DOI: https://doi.org/10.1016/j.spinee.2015.11.055
Author: Ways2Well Editorial Team
Reviewed by: Scientific Advisory Board member